Skip to main content

Maduck Sean's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Mar 20, 2024

Accession no.
0000950170-24-034264
Filed
Mar 20, 2024
Trade date
Mar 18-19, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $430.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maduck SeanCIK 0001698310Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 18, 2024Common StockMOption exerciseAcquired+17,219$3.88+$66,809.7292,441Direct
Mar 18, 2024Common StockSSaleDisposed−17,219$25.00−$430,47575,222Direct
Mar 19, 2024Common StockMOption exerciseAcquired+10,000$2.61+$26,10085,222Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 18, 2024Common StockMOption exerciseDisposed−17,219$0.00$0117,939Direct
Mar 19, 2024Common StockMOption exerciseDisposed−10,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

Read the full filing on SEC EDGAR (opens in a new tab)